2008
Utility of Cardiac Biomarkers in Predicting Infarct Size, Left Ventricular Function, and Clinical Outcome After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
Chia S, Senatore F, Raffel O, Lee H, Wackers F, Jang I. Utility of Cardiac Biomarkers in Predicting Infarct Size, Left Ventricular Function, and Clinical Outcome After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. JACC Cardiovascular Interventions 2008, 1: 415-423. PMID: 19463339, DOI: 10.1016/j.jcin.2008.04.010.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryBenzenesulfonatesBiomarkersCardiovascular AgentsCoronary AngiographyCreatine Kinase, MB FormDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionMyocardiumPiperazinesPredictive Value of TestsProportional Hazards ModelsProspective StudiesRisk AssessmentStroke VolumeTime FactorsTomography, Emission-Computed, Single-PhotonTreatment OutcomeTroponin ITroponin TUnited StatesVentricular Function, LeftConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionPrimary PCIElevation myocardial infarctionPercutaneous coronary interventionInfarct sizeClinical outcomesMyocardial infarctionCardiac biomarkersCoronary interventionCreatine kinaseCK-MBLarge ST-segment elevation myocardial infarctionTroponin TIntracellular calcium modulatorsLarger infarct sizeVentricular ejection fractionCardiac biomarker levelsLeft ventricular functionComposite clinical eventsTime-concentration curveEVOLVE trialLower LVEFAdverse eventsEjection fraction
2007
A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE)
Jang I, Weissman N, Picard M, Zile M, Pettigrew V, Shen S, Tatsuno J, Hibberd M, Tzivoni D, Wackers F, Investigators T. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE). American Heart Journal 2007, 155: 113.e1-113.e8. PMID: 18082500, DOI: 10.1016/j.ahj.2007.08.020.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryBenzenesulfonatesCardiac CatheterizationCombined Modality TherapyCoronary AngiographyDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleElectrocardiographyFemaleFollow-Up StudiesHumansInfusions, IntravenousMaleMiddle AgedMyocardial InfarctionPiperazinesProbabilityReference ValuesRisk AssessmentSalvage TherapyStroke VolumeSurvival RateTreatment OutcomeVentricular Function, LeftConceptsPrimary percutaneous coronary interventionLeft ventricular ejection fractionST-elevation myocardial infarctionPrimary PCIMCC-135Percutaneous coronary interventionAcute myocardial infarctionInfarct sizeMyocardial infarctionDay 5Coronary interventionClinical outcomesCalcium overloadPreservation of LVEFAcute ST-elevation myocardial infarctionEnd pointTarget populationComposite clinical outcomeLeft Ventricular SalvagePlacebo-controlled studyPrimary end pointSecondary end pointsLow-dose groupVentricular ejection fractionHigh-dose group
1996
Distortion of the Terminal Portion of the QRS on the Admission Electrocardiogram in Acute Myocardial Infarction and Correlation With Infarct Size and Long-Term Prognosis (Thrombolysis In Myocardial Infarction 4 Trial)**This study was supported in part by a grant from SmithKline Beecham, Philadelphia, Pennsylvania.
Birnbaum Y, Kloner R, Sclarovsky S, Cannon C, McCabe C, Davis V, Zaret B, Wackers F, Braunwald E. Distortion of the Terminal Portion of the QRS on the Admission Electrocardiogram in Acute Myocardial Infarction and Correlation With Infarct Size and Long-Term Prognosis (Thrombolysis In Myocardial Infarction 4 Trial)**This study was supported in part by a grant from SmithKline Beecham, Philadelphia, Pennsylvania. The American Journal Of Cardiology 1996, 78: 396-403. PMID: 8752182, DOI: 10.1016/s0002-9149(96)00326-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAngina PectorisCardiac Output, LowCoronary AngiographyCreatine KinaseDouble-Blind MethodElectrocardiographyFemaleFollow-Up StudiesHumansMaleMiddle AgedMyocardial InfarctionPatient AdmissionPrognosisRecurrenceRetrospective StudiesStroke VolumeSurvival RateTechnetium Tc 99m SestamibiThrombolytic TherapyTreatment OutcomeVentricular Function, LeftConceptsAcute myocardial infarctionLong-term prognosisAnterior acute myocardial infarctionCreatine kinase releaseInfarct sizeMyocardial infarctionMyocardial infarction (TIMI) 4 trialAnterior AMI patientsOne-year mortalityCoronary angiographic findingsLarger infarct sizeVentricular ejection fractionAdmission electrocardiogramHospital mortalityPrevious anginaSestamibi defectsAngiographic findingsBaseline characteristicsEjection fractionHeart failureAMI patientsClinical outcomesQRS distortionPatientsEnd point
1995
Relationship between reverse redistribution on planar thallium scintigraphy and regional myocardial viability: a correlative PET study.
Soufer R, Dey H, Lawson A, Wackers F, Zaret B. Relationship between reverse redistribution on planar thallium scintigraphy and regional myocardial viability: a correlative PET study. Journal Of Nuclear Medicine 1995, 36: 180-7. PMID: 7830110.Peer-Reviewed Original ResearchConceptsPlanar thallium scintigraphyCardiac eventsThallium scintigraphyReverse redistributionChronic coronary artery diseasePET viabilityAbnormal regional wall motionPlanar thallium imagesMyocardial Infarction trialPercent of patientsFuture cardiac eventsFuture cardiovascular eventsCoronary artery diseaseFavorable clinical outcomeMyocardial metabolic activityRegional wall motion analysisRegional wall motionPercent of segmentsWall motion analysisPET criteriaCardiovascular eventsReperfusion therapyArtery diseaseClinical outcomesPrognostic value
1987
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy Seven-year experience using serial radionuclide angiocardiography
Schwartz R, McKenzie W, Alexander J, Sager P, D'Souza A, Manatunga A, Schwartz P, Berger H, Setaro J, Surkin L, Wackers F, Zaret B. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy Seven-year experience using serial radionuclide angiocardiography. The American Journal Of Medicine 1987, 82: 1109-1118. PMID: 3605130, DOI: 10.1016/0002-9343(87)90212-9.Peer-Reviewed Original ResearchConceptsClinical congestive heart failureCongestive heart failureVentricular ejection fractionAbsolute left ventricular ejection fractionLeft ventricular ejection fractionHeart failureEjection fractionDoxorubicin therapyMild congestive heart failureClinical predictor variablesDiscontinuation of doxorubicinTotal cumulative dosageHigh-risk patientsHigh-risk subsetMajority of patientsHigh cumulative doseCommunity hospital settingProportional hazards regressionSeven-year experienceCommunity hospital environmentSerial radionuclideLast followVentricular dysfunctionClinical outcomesRoutine therapy